TNF and COVID-19: Based on these lines of evidence, the use of anti-TNF-α monoclonal antibodies, largely employed for autoimmune diseases, has been proposed in COVID-19 with the aim of inhibiting this cytokine and thus reducing the inflammatory effects triggered by this cytokine.